Royalty Pharma plc Class A Ordinary Shares
RPRX
$0.00
+0.17%
Royalty Pharma is the world's largest buyer of biopharmaceutical royalties, operating in the biotechnology industry. It is defined by its unique business model of acquiring royalty interests in commercial and development-stage therapies, providing a diversified revenue stream from over 35 products.…
RPRX
Royalty Pharma plc Class A Ordinary Shares
$0.00
Investment Opinion: Should I buy RPRX Today?
Based on a synthesis of the technical, fundamental, and valuation data, the objective assessment for RPRX is a 'Hold'. The stock's powerful uptrend and low forward P/E of 8.81 are strong bullish signals. However, its position at a 52-week high, elevated trailing valuation multiples, and recent quarterly earnings volatility suggest limited near-term upside and increased risk of consolidation. Investors may find better entry points on a pullback.
Sign up to view all
RPRX 12-Month Price Forecast
The dissonance between the very low forward P/E and the stock trading at its peak creates a neutral, wait-and-see stance. The fundamental cash flow story is strong, but technical and valuation headwinds are significant in the short term.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Royalty Pharma plc Class A Ordinary Shares's 12-month outlook, with a consensus price target around $0.00 and implied upside of — versus the current price.
Average Target
$0.00
1 analysts
Implied Upside
—
vs. current price
Analyst Count
1
covering this stock
Price Range
$0 - $0
Analyst target range
Analyst consensus data for target price and ratings distribution is not available in the provided inputs. The institutional ratings list shows recent actions from major firms, all maintaining positive stances such as 'Buy' or 'Overweight' from Citigroup, Morgan Stanley, and TD Cowen. However, no sufficient analyst coverage data (e.g., consensus target price, number of analysts) is provided to summarize a Wall Street consensus.
Bulls vs Bears: RPRX Investment Factors
RPRX presents a compelling mix of strong technical momentum, high profitability, and an attractive forward earnings multiple. However, the stock trades at rich absolute valuation multiples and exhibits quarterly earnings volatility. The overall picture is positive but requires careful timing given its proximity to all-time highs.
Bullish
- Strong Technical Uptrend: Stock up 31% in 6 months, near 52-week high, showing robust momentum.
- Attractive Forward Valuation: Forward P/E of 8.81 is low, suggesting potential undervaluation relative to earnings growth.
- High Profitability Margins: Operating margin of 65.6% and net margin of 32.4% reflect efficient royalty model.
- Strong Free Cash Flow: TTM FCF of $2.49B supports dividends and future royalty acquisitions.
Bearish
- High Current Valuation Multiples: Trailing P/E of 21.65 and P/S of 7.02 are elevated, pricing in growth.
- Quarterly Earnings Volatility: Net income dropped from $288M in Q3 to $214M in Q4 2025.
- Moderate Financial Leverage: Debt-to-equity of 1.38 introduces interest rate and refinancing risk.
- Limited Liquidity Buffer: Current ratio of 0.97 indicates tight working capital management.
RPRX Technical Analysis
The stock has demonstrated a strong and sustained uptrend over the observed 180-day period, rising from approximately $36.49 in early October 2025 to close at $47.97 on March 31, 2026. This represents a significant gain, with the price nearly reaching its 52-week high of $47.98, indicating robust bullish momentum. Over the short term, the stock has outperformed the broader market, posting a 1-month gain of 3.81% and a 3-month gain of 24.15% against the S&P 500's declines of -5.25% and -4.63%, respectively. The stock's relative strength metrics are positive, with a 1-month relative strength of 9.06. The current price of $47.97 is at the very top of its 52-week range ($29.66 - $47.98), trading just $0.01 below the high. This positioning suggests the stock is at a critical technical juncture, with potential for a breakout or consolidation.
Beta
0.39
0.39x market volatility
Max Drawdown
-8.9%
Largest decline past year
52-Week Range
$30-$49
Price range past year
Annual Return
+55.3%
Cumulative gain past year
| Period | RPRX Return | S&P 500 |
|---|---|---|
| 1m | +2.3% | -4.3% |
| 3m | +25.0% | -4.0% |
| 6m | +34.7% | -2.0% |
| 1y | +55.3% | +22.2% |
| ytd | +25.0% | -3.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RPRX Fundamental Analysis
Revenue for Q4 2025 was $622 million, showing a year-over-year growth of 4.78% from the same quarter in 2024. However, net income of $214 million in Q4 2025 was lower than the $288 million reported in Q3 2025, indicating some quarterly volatility in profitability. The company maintains a high net margin of 32.4% and a strong operating margin of 65.6%, reflecting its asset-light royalty model. The company's financial health shows a debt-to-equity ratio of 1.38, indicating a moderate level of leverage. Cash flow generation is robust, with trailing twelve-month free cash flow of nearly $2.49 billion and consistent positive operating cash flow each quarter. The current ratio of 0.97 suggests current assets are slightly less than current liabilities, which is typical for its non-inventory-based business model. Operational efficiency is solid, with a return on equity (ROE) of 11.9% and a return on assets (ROA) of 5.15%. The company's asset turnover is low, which is characteristic of its capital-intensive royalty acquisition strategy rather than an operational inefficiency.
Quarterly Revenue
$621990000.0B
2025-12
Revenue YoY Growth
+0.04%
YoY Comparison
Gross Margin
+1.00%
Latest Quarter
Free Cash Flow
$2.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RPRX Overvalued?
Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (P/E) ratio. The trailing P/E ratio is 21.65, while the forward P/E is notably lower at 8.81, based on estimated EPS of $7.71. The PEG ratio is 1.04, suggesting the stock is fairly valued relative to its earnings growth expectations. Other valuation metrics include a Price-to-Sales (P/S) ratio of 7.02, an EV/EBITDA of 15.30, and a Price-to-Book (P/B) ratio of 2.58. Peer comparison data is not available in the provided inputs to contextualize these multiples against industry averages.
PE
21.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -10x~702x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.3x
Enterprise Value Multiple
Investment Risk Disclosure
The primary risks for Royalty Pharma stem from its business model and financial structure. Credit and concentration risk is inherent, as royalty payments depend on the commercial success of a limited portfolio of biopharma products; patent expirations or clinical failures for key drugs like Imbruvica or Tysabri could materially impact revenue. Financial risk is moderate, with a debt-to-equity ratio of 1.38, exposing the company to rising interest rates and refinancing challenges. Liquidity risk is present but manageable, with a current ratio of 0.97, though the model's strong cash generation mitigates this. Finally, valuation risk is elevated as the stock trades near its 52-week high with a trailing P/E over 21, making it susceptible to a pullback if growth expectations are not met or market sentiment shifts.
FAQ
Key risks include concentration risk, as royalties depend on ~35 products like Imbruvica and Tysabri. Financial leverage is moderate with a debt-to-equity of 1.38. Quarterly earnings have shown volatility, with net income dropping from $288M to $214M in recent quarters. Valuation risk is high as the stock trades at its peak, and the business model is exposed to the underlying biopharma product lifecycle.
The 12-month outlook is for consolidation with a neutral bias. The base case (50% probability) sees a trading range of $44 to $51, assuming the company meets its estimated EPS of $7.71. The bull case (30%) targets $52-$58 on positive catalysts, while the bear case (20%) could see a correction to $35-$43. The AI assessment is neutral with medium confidence, balancing strong fundamentals against high near-term prices.
RPRX sends mixed valuation signals. It appears potentially undervalued on a forward basis, with a P/E of 8.81 based on estimated EPS of $7.71. However, on a trailing basis, its P/E of 21.65 and Price-to-Sales of 7.02 are rich. The PEG ratio of 1.04 indicates it is roughly fairly valued relative to its earnings growth expectations. The current price at the 52-week high adds to valuation concerns.
RPRX is a high-quality company but may not be an ideal immediate purchase. Its strong uptrend has pushed the price to a 52-week high of $47.98, increasing near-term risk. While the forward P/E of 8.81 is compelling, the elevated trailing P/E of 21.65 suggests much growth is already priced in. A 'Hold' rating is appropriate, with buying opportunities likely on pullbacks.
RPRX is more suitable for long-term investors seeking stable, cash-generative assets in healthcare. Its low beta of 0.42 and dividend yield of 2.3% support a defensive, income-oriented long-term hold. Short-term trading is challenged by the stock's position at a 52-week high and potential for consolidation or pullback as it digests its significant recent gains.